UPDATED May 20, 2024
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
---|---|---|---|---|---|---|---|---|---|---|---|
GTHX | US$4.55 | -1.5% | 58.0% | US$236.8m | US$8.50 | PS2.8x | E48.3% | n/a | Pharmaceuticals & Biotech | ||
ACTD | US$7.79 | -24.2% | -21.2% | US$303.0m | US$17.00 | PE-25.3x | E85.2% | n/a | Diversified Financials | ||
ASTS | US$5.28 | 135.7% | -7.4% | US$1.2b | US$13.28 | PS1474.4x | E70.6% | n/a | Telecom | ||
OCUP | US$1.79 | 6.5% | -56.0% | US$43.2m | US$19.33 | PS2.4x | E51.0% | n/a | Pharmaceuticals & Biotech | ||
ZYNE | US$1.30 | 4.0% | 96.1% | US$65.6m | US$1.26 | PB2.3x | E67.2% | n/a | Pharmaceuticals & Biotech | ||
ZVRA | US$4.69 | -4.1% | -16.8% | US$198.0m | US$19.00 | PS7.1x | E65.3% | n/a | Pharmaceuticals & Biotech | ||
IVVD | US$2.25 | -5.1% | 58.5% | US$286.1m | US$9.23 | PB1.5x | E69.8% | n/a | Pharmaceuticals & Biotech | ||
FENC | US$7.31 | -27.0% | -0.8% | US$192.3m | US$16.83 | PE70.2x | E47.2% | n/a | Pharmaceuticals & Biotech | ||
AMPG | US$1.43 | -35.0% | -41.9% | US$14.0m | US$9.00 | PB0.5x | E107.0% | n/a | Tech | ||
PGEN | US$1.39 | 3.0% | 6.1% | US$348.3m | US$9.12 | PS64.5x | E58.1% | n/a | Pharmaceuticals & Biotech | ||
ARBB | US$0.88 | -3.4% | -78.5% | US$22.4m | US$3.00 | PB1.1x | E139.1% | n/a | Software | ||
AQMS | US$0.44 | -7.3% | -59.3% | US$49.2m | US$3.00 | PS2010.1x | E66.6% | n/a | Commercial Services | ||
SCPH | US$4.04 | -7.1% | -63.7% | US$171.3m | US$19.50 | PS8.3x | E63.3% | n/a | Pharmaceuticals & Biotech | ||
XELB | US$0.69 | -3.5% | -19.1% | US$17.7m | US$3.00 | PB0.3x | E114.9% | n/a | Retail | ||
REE | US$5.14 | 15.2% | -57.2% | US$54.0m | US$13.50 | PS34.6x | E55.6% | n/a | Automobiles | ||
IREN | US$6.36 | 31.1% | 57.4% | US$849.4m | US$11.43 | PS5.6x | E130.7% | n/a | Software | ||
SMSI | US$2.81 | 3.1% | -71.9% | US$29.0m | US$10.67 | PB0.7x | E81.8% | n/a | Software | ||
ATNM | US$9.69 | 9.4% | 8.3% | US$291.9m | US$25.40 | PS3563x | E68.5% | n/a | Pharmaceuticals & Biotech | ||
ETON | US$3.64 | 2.5% | -1.4% | US$93.0m | US$8.00 | PE102.4x | E117.7% | n/a | Pharmaceuticals & Biotech | ||
ALIM | US$3.16 | -9.2% | 23.9% | US$167.5m | US$8.00 | PS1.8x | E177.4% | n/a | Pharmaceuticals & Biotech | ||
ACIU | US$3.16 | -4.2% | 49.8% | US$298.8m | US$10.99 | PS18.3x | E62.1% | n/a | Pharmaceuticals & Biotech | ||
LTRX | US$3.86 | 2.7% | -20.9% | US$150.7m | US$7.60 | PB1.9x | E174.9% | n/a | Tech | ||
TVTX | US$6.17 | -2.7% | -63.6% | US$461.3m | US$14.86 | PS3x | E67.7% | n/a | Pharmaceuticals & Biotech | ||
VRCA | US$8.70 | -9.0% | 51.0% | US$367.8m | US$14.17 | PS41.4x | E65.9% | n/a | Pharmaceuticals & Biotech |